Hubei Goto BiopharmLtd Dividends and Buybacks
Dividend criteria checks 0/6
Hubei Goto BiopharmLtd is a dividend paying company with a current yield of 0.1%.
Key information
0.1%
Dividend yield
-1.3%
Buyback Yield
| Total Shareholder Yield | -1.2% |
| Future Dividend Yield | n/a |
| Dividend Growth | -107.9% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | CN¥0.016 |
| Payout ratio | -14% |
Recent dividend and buyback updates
Recent updates
Hubei Goto Biopharm Co.,Ltd. (SZSE:300966) Shares Fly 42% But Investors Aren't Buying For Growth
Oct 09
Hubei Goto Biopharm Co.,Ltd. (SZSE:300966) Held Back By Insufficient Growth Even After Shares Climb 26%
May 12Hubei Goto BiopharmLtd's (SZSE:300966) Soft Earnings Are Actually Better Than They Appear
May 02Lacklustre Performance Is Driving Hubei Goto Biopharm Co.,Ltd.'s (SZSE:300966) Low P/S
Feb 28Stability and Growth of Payments
Fetching dividends data
Stable Dividend: 300966 is not paying a notable dividend for the CN market, therefore no need to check if payments are stable.
Growing Dividend: 300966 is not paying a notable dividend for the CN market, therefore no need to check if payments are increasing.
Dividend Yield vs Market
| Hubei Goto BiopharmLtd Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (300966) | 0.1% |
| Market Bottom 25% (CN) | 0.5% |
| Market Top 25% (CN) | 2.1% |
| Industry Average (Biotechs) | 1.3% |
| Analyst forecast (300966) (up to 3 years) | n/a |
Notable Dividend: 300966's dividend (0.1%) isn’t notable compared to the bottom 25% of dividend payers in the CN market (0.55%).
High Dividend: 300966's dividend (0.1%) is low compared to the top 25% of dividend payers in the CN market (2.12%).
Earnings Payout to Shareholders
Earnings Coverage: 300966 is not paying a notable dividend for the CN market.
Cash Payout to Shareholders
Cash Flow Coverage: 300966 is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 09:45 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hubei Goto Biopharm Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|